BDC Laboratories is partnering with the Dilawri Cardiovascular Institute (DCI) to enhance the development and clinical validation of cardiovascular medical devices. Our collaboration coincides with the launch of DCI’s Center for Cardiovascular Translational Science, an institute that will lead the way in cardiovascular innovation, research, and clinical care.
The Center for Cardiovascular Translational Science will serve as a hub to drive initiatives in device testing and simulation to serve academic, clinical, and industry partners, from start-ups to well-established device makers, with a particular emphasis on transcatheter heart valve technologies.
Its mission is to bridge the gap between bench and bedside with a focus on the development of new devices and expanded indications for existing ones. This includes efforts such as evaluating bioprosthetic valve performance or re-intervention techniques.
“We integrate both biological and engineering components to build more clinically representative models that reflect the real challenges our clinical colleagues face every day,” said Stephanie Sellers, PhD, Director of the Center for Cardiovascular Translational Science. “Our goal is to help our partners develop truly excellent devices. If our models can shift the needle even one percent in terms of clinical outcomes, that’s a meaningful win.”
Achieving Better Clinical Outcomes Through Strategic Collaboration
To support this work, BDC Laboratories will initially outfit the center with our high-performance HDTi-6000 pulse duplicator, a repeatable, reproducible, and adaptable test platform designed to simulate real-world clinical conditions with regulatory-grade precision.
BDC Laboratories’ active R&D group is committed to aligning test systems with the evolving realities of cardiovascular care. We actively work with voices across clinical, regulatory, and industry channels to continuously refine our solutions and help device developers deliver safe, effective devices.
“Innovation in this field often moves faster than the regulatory guidance documents utilized for evaluation,” said Craig Weinberg, PhD, CTO of BDC Laboratories. “Our R&D group works closely with clinical experts, like Stephanie’s team, as well as industry and regulatory leaders, to make sure our testing solutions reflect where the field is going while simultaneously maintaining alignment with current requirements. Whether the end user is submitting to regulators, exploring novel device concepts, or conducting academic research, we’re focused on helping drive innovation that’s both clinically relevant and regulatory aligned.”
Explore the Dilawri Cardiovascular Institute online.
To learn more about this partnership, see the full news release.